Public awareness and tighter prescribing restrictions linked to decline in pregabalin misuse
· Medical Xpressedited by Swati Mestri, reviewed by Andrew Zinin
Swati Mestri
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
Unlike in many other developed countries, rates of pregabalin use and overdose have leveled off and declined in Australia since 2018 following high-profile media coverage of harms, restrictions on prescriptions and supply, and new boxed warnings, finds a study published by The BMJ.
Compared with earlier trends, prescriptions were 25% lower and intentional poisoning calls 47% lower than expected, the results show.
While the researchers can't establish a direct (causal) link between this decline and these measures, they say the results are promising and may help inform similar interventions elsewhere.
Pregabalin is a gabapentinoid drug used to treat epilepsy, nerve pain and anxiety disorders. Alongside increased use in recent years, there is mounting evidence of misuse, dependence and harms in Europe, the U.S., Asia and Australia.
For example, in the U.K., one-third of substance use deaths involve a gabapentinoid, predominantly pregabalin, and deaths involving gabapentinoids more than doubled between 2018 and 2022. Similar concerns have been reported elsewhere, prompting many countries to implement restrictions and interventions.
To evaluate recent trends in pregabalin use and misuse across Australia, researchers examined dispensing claims and poison center data from 2016 to 2024 with a focus on three key events: widespread media reporting on the harms of pregabalin in December 2018, tighter prescribing restrictions from April 2020 and the introduction of boxed warnings in February 2021.
During the study, 3,441,851 pregabalin prescriptions were dispensed to 227,864 people, and 4,871 pregabalin overdose calls were reported to the poison center.
Pregabalin use and overdose peaked in 2018 before declining. Three time points were observed when pregabalin dispensing decreased significantly: in December 2018 (corresponding to high-profile press coverage), in May 2020 (the month after tighter prescribing restrictions were introduced) and in December 2021 (following boxed warnings and the introduction of real-time prescription monitoring).
Compared with the projected historical trend, there was a 25% decrease in dispensing, with approximately 118,390 fewer pregabalin prescriptions in December 2021, and an ongoing reduction of 0.7% each month. There was also a 47% decrease in overdose rates, with an estimated 41 fewer pregabalin overdose calls in December 2021, and an ongoing reduction of 1.6% each month.
These are observational findings, and the researchers acknowledge that they relied on subsidized prescriptions only, that poison center data are subject to reporting bias, and that they were unable to report access to pain treatment and switching to other drugs, such as opioids. Nonetheless, findings were consistent after further analyses, suggesting they are robust.
As such, they say, after many years of escalating pregabalin use and overdose in Australia, rates appear to have plateaued and started to decline since 2018.
And although they can't attribute causality, they note that this decline coincided with widespread media coverage of harms, prescribing restrictions and boxed warnings, and they suggest similar measures could be considered in other countries where pregabalin misuse is of concern.
However, while these findings are positive, they point out that pregabalin use and overdose remain high, with dispensing rates still far outstripping what would be expected if pregabalin were prescribed for approved indications alone, prompting them to call for ongoing monitoring and further restrictions.
These figures are striking but warrant caution, says professor David Juurlink in a linked editorial, arguing that pregabalin should be used more selectively and only when patients experience meaningful benefit.
He cautions against viewing it as a safe everyday analgesic, advising it be reserved for proven conditions such as diabetic nerve pain and chronic widespread pain (fibromyalgia), while avoiding it for low back pain and sciatica.
"Persisting with ineffective treatment or escalating the dose in pursuit of relief that has yet to materialize is more than misplaced optimism. It is an invitation to harm," he warns.
Publication details
The BMJ (2026). DOI: 10.1136/bmj-2026-101021
Journal information: British Medical Journal (BMJ)
Key medical concepts
Clinical categories
Clinical pharmacology Provided by British Medical Journal Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Public awareness and tighter prescribing restrictions linked to decline in pregabalin misuse (2026, November 11) retrieved 12 November 2026 from https://medicalxpress.com/news/2026-11-awareness-tighter-restrictions-linked-decline.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.